Dr. Susanna Jeurling
MD · Internal Medicine, Rheumatology
Dr. Susanna Jeurling is double Board certified in both Internal Medicine and Rheumatology through the American Board of Internal Medicine. She see patients both for primary care and consultative rheumatology.
A native of Washington, D.C., Dr. Jeurling earned her Bachelor of Science in Molecular Biochemistry and Biophysics from Yale University with Distinction. She received her medical degree from New York University School of Medicine where she was inducted into the Alpha Omega Alpha medical honor society and conducted research on cardiovascular risk. She completed her Internal Medicine internship and residency at the Hospital of the University of Pennsylvania. Dr Jeurling returned to the mid-Atlantic for her Rheumatology fellowship at Johns Hopkins, where she continues to serve as a clinical instructor — teaching fellows and collaborating on ongoing research.
Dr. Jeurling offers patients the time, attention, and continuity that thoughtful care requires.
Board Certifications
- Internal Medicine — American Board of Internal Medicine
- Rheumatology — American Board of Internal Medicine
Research & Publications
Patel S, Jeurling S, Albayda J, Tiniakou E, Kang J. Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series. Rheumatology 2025;64(12): 6354-6358.
Jeurling, S; Cappelli, LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Current Opinion in Rheumatology 2020;32(3):315-320.
Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, Xia Y, Fisher MC, Slobodnick A, Tenner CT, Katz SD. Colchicine use and incident coronary artery disease in male patients with gout. Canadian Journal of Cardiology. 2020;36(11):1722-8.
Pobezinsky LA, Etzensperger R, Jeurling S, Alag A, Kadakia T, McCaughtry TM, Kimura MY, Sharrow SO, Guinter TI, Feigenbaum L, Singer A. Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function. Nature Immunology. 2015;16(5):517-24.
Jeurling S. Lung Cancer Screening with Low-Dose CT Scans. Clinical Correlations 2014.
Katz G, Pobezinsky LA, Jeurling S, Shinzawa M, Van Laethem F, Singer A. T cell receptor stimulation impairs IL-7 receptor signaling by inducing expression of the microRNA miR-17 to target Janus kinase 1. Science Signaling. 2014;7(340):ra83-ra83.
Pobezinsky LA, Angelov GS, Tai X, Jeurling S, Van Laethem F, Feigenbaum L, Park JH, Singer A. Clonal deletion and the fate of autoreactive thymocytes that survive negative selection. Nature Immunology. 2012;13(6):569-78.
Tikhonova AN, Van Laethem F, Hanada KI, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling S, Bernhardt G, Park JH, Yang JC. αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity. 2012;36(1):79-91.